20 April 2022 in Frontiers in Immunology
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a malignancy characterized by the aberrant accumulation of immature B-cell precursors in bone marrow and other lymphoid organs. Although several intrinsic regulatory signals participating in BCP-ALL have been clarified, detailed intrinsic and extrinsic mechanisms that regulate BCP-ALL progression have not been fully understood. In the current study, we report that miR-582 is downregulated in BCP-ALL cells compared with normal B cells. Forced overexpression of miR-582 attenuated BCP-ALL cell proliferation and survival. We found that miR-582 overexpression disturbed the mitochondrial metabolism of BCP-ALL cells, leading to less ATP but more ROS production. Mechanistically, we identified PPTC7 as a direct target of miR-582. MiR-582 overexpression inhibited the activity of CoQ10, which is downstream of PPTC7 and played an important positive regulatory role in mitochondrial electron transportation. Finally, we found that overexpression of miR-582 upregulated the expression of immune checkpoint molecule CD276 and reduced NK cell-mediated cytotoxicity against BCP-ALL cells. CD276 blockade significantly increased NK cell-mediated cytotoxicity against miR-582-overexpressing BCP-ALL cells. Together, our research demonstrates that miR-582 acts as a negative regulator of BCP-ALL cells by reducing proliferation and survival, but protects BCP-ALL cells from NK cell-mediated cytotoxicity, suggesting that miR-582 may be a new therapeutic biomarker for BCP-ALL with CD276 blocker.
29 August 2025 in Biophysics Reviews
Respiratory diseases represent a substantial global health challenge, underscoring an urgent need for the development of better diagnostic tools and effective therapeutics. Recently, mechanical biomarkers have emerged as crucial pathophysiological indicators of most human diseases detectable at cell, tissue, and organ level. They present a promising alternative to traditional biochemical markers, with label-free, cost-effective, and rapid diagnostic advantages. This review provides a comprehensive summary of the cross-scale techniques for probing mechanical biomarkers and the manifestation of mechanical biomarkers in major chronic respiratory diseases including asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), and lung cancer. Then, the diagnostic and informed therapeutic applications of mechanical biomarkers in respiratory medicine are discussed. Moreover, it addresses the challenges and future research directions for further understanding and integration of mechanical biomarkers into respiratory disease and medicine. In summary, this review provides an overview of the current landscape and future prospects of the role of mechanical biomarkers in combating respiratory diseases from bench to bedside as a new frontier of mechanomedicine.